Benzinga.com

1ADIL : EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Thursday announced that the FDA has granted the company's request for an End of Phase 2 meeting to discuss its proposed clinical development plan and seek ...
Seeking Alpha

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

Meeting’s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (ADIL) (“Adial” or the “Company”), ...
Benzinga.com

Cognition Therapeutics Surges 30% Pre-Market After FDA Backs Phase 3 Trial Design For Alzheimer's Drug

What Happened: The New York-based clinical-stage biopharmaceutical company received final meeting minutes from the U.S. Food and Drug Administration confirming alignment on a registrational path for ...
Business Wire

PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

Feedback from U.S. Food and Drug Administration (FDA) supports advancement into a pivotal Phase 3 trial and a 505(b)(2) regulatory pathway Phase 3 SURPASS-IPF trial remains on track to be initiated by ...